Kexing Biopharm’s Innovative Drug GB19 Received Approval From FDA To Conduct Clinical Trials

Recently, GB19 Injection, independently developed by Shenzhen Kexing Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Kexing Biopharm, has officially received an Investigational New Drug (IND) approval notice from the U.S. Food and Drug Administration (FDA), allowing clinical trials to be conducted in the United States. The indication is for the treatment of cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE).

Regulatory Approval Details

Drug name: GB19 Injection

Application purpose: Conduct clinical trials in the United States

Application number: IND 180417

Review conclusion: The FDA has approved the IND application for this investigational drug and agreed that clinical studies may be conducted in accordance with the submitted protocol.

Drug Overview

GB19 Injection targets BDCA2, a receptor specifically expressed on the surface of plasmacytoid dendritic cells (pDCs). Its mechanism of action is distinct from that of currently approved therapies that primarily targeting the B-cell pathway. By specifically binding to BDCA2, GB19 inhibits the production of type I interferon by pDC cells, thereby modulating the pathogenic feedback loops between innate and adaptive immunity.

In preclinical studies ,GB19 demonstrated high potency, favorable bioavailability, sustained target inhibition for over 90 days, low immunogenicity, and an excellent safety profile.  If successfully developed, it is expected to provide a new treatment options for patients with autoimmune diseases associated with interferon pathway dysregulation including SLE.

Lupus erythematosus is a serious autoimmune disease that significantly affects human health, with a large global patient population and a strong unmet clinical need for safer and more effective innovative therapies. Previously, this project had already been approved for clinical trials by the National Medical Products Administration (NMPA) in China.

GB19 adopts a simultaneous submission strategy in both China and the United States, marking an important breakthrough in the company’s innovation-driven R&D and global expansion in the autoimmune field. In addition to GB19, several innovative drug programs such as GB05 (human interferon inhalation solution) and GB18 (cancer cachexia treatment) have also achieved dual IND filings in China and the U.S., demonstrating the continuous execution of Kexing Biopharm’s “innovation + globalization” strategy.

https://www.kexingbiopharm.com/
Kexing Biopharm

  • Related Posts

    Choosing an IC Chip Card Manufacturer: What Matters Beyond the Card Itself?
    • adminadmin
    • November 20, 2026

    An IC chip card may look like a simple plastic card, but its performance depends on several components working together: the chip, antenna, card material, manufacturing process, and compatibility with…

    Continue reading
    From Fragrance to Form: How the Right DIY Candle Mold Shapes a Better Handmade Candle
    • adminadmin
    • November 20, 2026

    Creating a scented candle is about more than choosing wax and fragrance. Its shape, surface texture, and decorative details also influence how the finished product looks and feels. For candle…

    Continue reading

    Leave a Reply

    Mechanical Equipment & Tool Parts

    Automatic Inverted Vertical Drawing Equipment: How to Improve Heavy Wire Processing Efficiency

    • November 20, 2026

    Three Flames, Better Control: What to Look for in a Windproof Triple Jet Lighter

    • November 20, 2026

    COB LED Screen Technology for Better Fine Pitch Display Performance

    • November 20, 2026

    Stator Laser Welding Machine for Strong and Precise Motor Welding

    • November 20, 2026

    PE Geocell Sheet Production Line for Stable Infrastructure Material Manufacturing

    • November 20, 2026

    FSH-LA Series Linear Injection Pump System for Precision Electrolyte Filling in Lithium-Ion Battery Manufacturing

    • November 20, 2026